Characterization of a Ruthenium(III)/NAMI-A Adduct with Bovine Serum Albumin that Exhibits a High Anti-Metastatic Activity

An exchange for the better: X‐ray absorption spectroscopic studies show that treatment of an RuIII drug, NAMI‐A, with bovine serum albumin (BSA) results in complete replacement of the Cl− and S‐donor ligands with N‐donor and carboxylato residues of the protein (see scheme). The RuIII–BSA adduct is as active in enhancing the cell–substrate interactions as the original NAMI‐A complex (which converts into RuIII–BSA within minutes in the cell‐culture medium).